Stockscreener 앱 받기
19.38
3.97%
0.74
시간 외 거래:
19.35
-0.03
-0.15%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says - marketscreener.com
Denali stock dips as Biogen-partnered Parkinson's disease study fails - MSN
Biogen and Denali discontinue Parkinson’s candidate BIIB122 after Phase IIb LUMA study miss - Manufacturing Chemist
Biogen, Denali to drop Parkinson’s therapy after mid-stage trial setback - MSN
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Understanding the Setup: (DNLI) and Scalable Risk - Stock Traders Daily
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Is Early AVLAYAH Demand Reshaping The Investment Case For Denali Therapeutics’ Rare-Disease Platform (DNLI)? - Sahm
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating - Moomoo
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating - Moomoo
Denali Therapeutics stock falls after Parkinson’s drug fails trial By Investing.com - Investing.com South Africa
Denali Therapeutics stock falls after Parkinson’s drug fails trial - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating - marketscreener.com
Biogen, Denali to drop Parkinson’s therapy (BIIB:NASDAQ) - Seeking Alpha
Parkinson’s drug from Biogen, Denali comes up short - Yahoo Finance
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints - TradingView
Biogen, Denali scrap Parkinson’s candidate after Phase IIb miss - The Pharma Letter
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study - 1470 & 100.3 WMBD
Biogen, Denali discontinue Parkinson’s drug after trial fails By Investing.com - Investing.com Nigeria
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data - Stock Titan
Biogen and Denali Therapeutics Halt BIIB122 Development After Tr - GuruFocus
Biogen, Denali discontinue Parkinson’s drug after trial fails - Investing.com UK
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results - GuruFocus
[8-K] Denali Therapeutics Inc. Reports Material Event - Stock Titan
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - GlobeNewswire Inc.
Denali Therapeutics stock (US24823R1077): New data keeps biotech in focus - AD HOC NEWS
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval - Yahoo Finance
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval - sharewise.com
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI) - Stock Titan
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate - BioSpace
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):